Travere Said It Received 459 New Patient Start Forms For Filspari (Sparsentan) In Q4 Of 2023; Preliminary Net Product Sales Of Filspari Totaled $15M For Q4 And $30M Since The Beginning Of Commercial Launch In February 2023.
Portfolio Pulse from Benzinga Newsdesk
Travere Therapeutics reported receiving 459 new patient start forms for Filspari (Sparsentan) in Q4 2023. Preliminary net product sales for Filspari reached $15M in Q4 and totaled $30M since its commercial launch in February 2023.
January 08, 2024 | 12:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Travere Therapeutics reported significant Q4 growth for Filspari, with 459 new patients and $15M in sales for the quarter, contributing to a total of $30M in sales since launch.
The reported increase in patient starts and sales for Filspari suggests strong market acceptance and growth potential for Travere. This positive sales data is likely to be viewed favorably by investors, potentially leading to a short-term increase in TVTX stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100